

FOI REF: 26/388

2<sup>nd</sup> July 2026

Eastbourne District General Hospital

Kings Drive  
Eastbourne  
East Sussex  
BN21 2UD

Tel: 0300 131 4500  
Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

• Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	53
• Abemaciclib + Fulvestrant	0
• Alpelisib + Fulvestrant	1
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only	14
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel	0
• Atezolizumab	0
• Capivasertib	2
• Capecitabine as a single agent	23
• Carboplatin + Paclitaxel	4
• Elacestrant	4
• Eribulin as a single agent or in combination	3
• Everolimus + Exemestane	0
• Fulvestrant as a single agent	0
• Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	23
• Palbociclib + Fulvestrant	6
• Parp Inhibitors (Olaparib/Talazoparib)	1
• Pembrolizumab Monotherapy	3
• Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	4
• Carboplatin + Paclitaxel + Pembrolizumab	9
• Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	1
• Phesgo (Pertuzumab + Trastuzumab in a single injection)	45

• Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	79
• Ribociclib + Fulvestrant	30
• Sacituzumab Govitecan	1
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	25
• Trastuzumab deruxtecan (Enhertu)	0
• Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	35
• Trastuzumab emtansine (Kadcyla)	8
• Any other active systemic anti-cancer therapy	29
• Pembrolizumab subcutaneous injection	0

2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	45	25	20
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	1	1	0
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	35	25	10
Trastuzumab deruxtecan (Enhertu)	0	0	0
Trastuzumab emtansine (Kadcyla)	8	8	0
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	53	51	0
Abemaciclib + Fulvestrant	0	0	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	79	32	47
Ribociclib + Fulvestrant	30	1	29
Capecitabine as a single agent	23	3	20
Carboplatin + Paclitaxel	4	2	2
Carboplatin + Paclitaxel + Pembrolizumab	9	9	0

**3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.**

Currently we have no clinical research trials open to recruitment.

We have the following clinical research trials that are closed to recruiting new patients but are in follow up status:

IRAS Number	Trial Name	Number of Participants recruited
329586	SWITCH: Understanding side effects experienced by women prescribed hormone therapy	42
N/A	Persephone: Duration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelve	91
137785	POSNO: POSitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes.	23
20104	Add Aspirin Breast Cohort: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.	18

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at [esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net) quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team  
East Sussex Healthcare NHS Trust  
0300 131 4716  
Core Hours of Business: Monday to Friday 9.00am to 4.00pm